重组抗人CD4单抗(OKT4) | Syd Labs PA007384.m2b
体内实验级重组抗人CD4单克隆抗体，小鼠IgG2b Kappa（克隆号：OKT4，Syd Labs货号：PA007384.m2b），纯度>95%，适用于体外和体内研究。其不变区为小鼠Mouse IgG2b Kappa (mIgG2b或m2b)，可与重组小鼠IgG2b同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007384.m2b |
|---|---|
| 产品名称 | 重组抗人CD4单抗(OKT4) | Syd Labs PA007384.m2b |
| 英文名 | In Vivo Grade Recombinant Anti-human CD4 Monoclonal Antibody (Clone: OKT4), Mouse IgG2b Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇4，leu-3，T4 |
| 概述 | Syd Labs提供重组小鼠IgG2b同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | OKT4 |
| 同种型 | 小鼠 IgG2b kappa |
| 免疫源 | 抗人CD4单克隆抗体（克隆：OKT4）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD4单克隆抗体，小鼠 IgG2b Kappa(克隆号OKT4)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007384.m2b Syd Labs提供重组小鼠IgG2b同型对照抗体和重组人IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人CD4蛋白影响的生物学途径的测定。 |
文献
抗人CD4单克隆抗体，体内实验级重组，小鼠IgG2b Kappa (克隆号OKT4)（In Vivo Grade Recombinant Anti-human CD4 Monoclonal Antibody (Clone: OKT4), Mouse IgG2b Kappa，货号：PA007384.m2b Syd Labs）
重组 OKT4 抗体可与人 CD4 蛋白（CD4 分子）结合，这是一种糖蛋白，也是 T 细胞受体（TCR）的共受体。CD4 蛋白表达于多种免疫细胞表面，如辅助性 T 细胞、单核细胞、巨噬细胞和树突状细胞。
抗人CD4单抗(OKT4)部分引用文献:
1. Administration of prednisolone in vivo affects the ratio of OKT4/OKT8 and the LDH-isoenzyme pattern of human T lymphocytes
Tenbergen, F., et al. Clin Immunol Immunopathol. 1984 Feb;30(2):191-202. PMID: 6607798
“The OKT4 antibody (anti-human CD4) was used to assess T lymphocyte subsets in healthy volunteers treated with prednisolone (10, 30, or 60 mg). …Prednisolone induced T lymphocytopenia, preferentially affecting OKT4+ cells, leading to a decreased OKT4/OKT8 ratio and altered lactate dehydrogenase isoenzyme patterns, with effects varying by dose and time post-administration.”
2. In vivo activated cytotoxic T cells in the thyroid infiltrate of patients with Hashimoto’s thyroiditis
Del Prete, G. F., et al. Clin Exp Immunol. 1986 Jul;65(1):140-7. PMID: 3024884
“The OKT4 antibody (anti-human CD4) was used with complement for negative selection to enrich T8+ cells in thyroid-infiltrating lymphocytes from Hashimoto’s thyroiditis patients. …High T8+ cell proportions with an inverted T4/T8 ratio were observed, and OKT4 helped confirm low CD4+ cell presence in TAC+ T cell populations.”
3. Human CD4 modulation in vivo induced by antibody treatment
Horneff, G., et al. Clin Immunol Immunopathol. 1993 Jan;66(1):80-90. PMID: 8440076
“The OKT4 antibody (anti-human CD4) was used to monitor CD4 modulation in vivo after anti-CD4 antibody (MAX.16H5) treatment. …CD4 antigen density was reduced to 30% within 1 hour and remained down-modulated for up to 28 days, with depletion of CD4+ cells observed in both responders and non-responders to therapy.”
4. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
Jin, X., et al. J Exp Med. 1999 Mar 15;189(6):991-1000. PMID: 10075982
“The OKT8F antibody (anti-human CD8) was used to deplete CD8+ cells in SIV-infected macaques, resulting in a 99.9% reduction in peripheral blood CD8 cells and a 70-fold increase in plasma viremia. …The OKT4 antibody (anti-human CD4) was used to assess the resting CD4+ T cell pool, revealing increased productively infected cells.”
5. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody
Rijlaarsdam, J. U., et al. Eur J Immunol. 1982 Nov;12(11):979-82. PMID: 6759145
“The OKT4 antibody (anti-human CD4) was used to confirm stable CD4 expression on T cells during OKT3 treatment, which rapidly modulated the OKT3 epitope within 30 minutes via internalization. …OKT4 and OKT8 epitopes remained unaffected, with OKT4 aiding in monitoring T-cell populations during transient lymphocytopenia.”